NHS Fast-Tracks Glofitamab, Expanding Curative Options for Aggressive Lymphoma
Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from the National Institute for Health…